期刊文献+

非病毒基因载体的递送屏障及其提高基因递送效率的研究进展 被引量:2

Research Progress in Gene Delivery Barriers of Non-viral Vectors and Its Improving Gene Delivery Efficiency
下载PDF
导出
摘要 随着肿瘤基因治疗研究的逐渐深入,其临床应用逐渐增多,其中载体的选择是基因治疗的主要难题。非病毒基因载体由于安全性高,毒性低,免疫原性低,制备简单等突出优点而具有良好的应用前景,其缺点是转染效率低,主要是由于在非病毒载体介导基因治疗中存在三道屏障,即细胞膜、内涵体-溶酶体系统、核膜;因此,要提高非病毒载体基因转染效率,就要保证载体系统有效跨越三道屏障将目的基因成功运送至靶部位。综述非病毒基因载体的递送屏障以及提高基因递送效率的研究进展文献,并对其研究进展做了简要分析。 Gene therapy possesses a tremendous potential for the successful treatment of cancer with the research development of it. A major problem in the application of cancer gene therapy is the lack of a safe and efficient delivery system for nucleic acids. Non-viral vectors have shown a promising perspective because of their high safety, low toxicity, low immunogenicity, easy preparation and other prominent points. And its disadvantage of low transfection efficiency is mainly due to the presence of three barriers in non-viral vectors mediated gene therapy: the cell membrane, endosome- lysosome system, and the nuclear envelope. Therefore, to improve the gene transfection efficiency of non- viral vectors, it is necessary to ensure that the vector systems pass across the three barriers and transfer gene to target sites successfully. The literatures about gene delivery barriers of non-viral vectors and the research progress of improving the gene delivery efficiency are summarized, and a brief analysis on the research progress is made.
出处 《抗感染药学》 2015年第4期487-493,共7页 Anti-infection Pharmacy
关键词 基因治疗 非病毒载体 屏障 Gene therapy Non-viral vectors barriers
  • 相关文献

参考文献2

二级参考文献100

  • 1何朝辉,孔桦,许海燕.药物和基因载体树枝状大分子的生物学效应及表面修饰研究进展[J].中国医学科学院学报,2006,28(4):590-595. 被引量:2
  • 2李双艳,郝丽娟,韩磊,黄杰,常津.赖氨酸修饰壳聚糖磁性超微载体的制备和表征[J].高分子通报,2007(7):32-40. 被引量:7
  • 3Tomalia D. A., Baker H., Dewald J., Hall M., Kallos G., Martin S., Roeck J., Ryder J., Simthp P.. Polym. J.[J], 1985, 17(1): 117-132.
  • 4Vogtle F., Gestermann S., Hesse R., Schwierz H., Windisch B.. Prog. Polym. Sci.[J], 2000, 25(7): 987-1041.
  • 5Kristen S., James P. T.. Rev. Mol. Biotechnol.[J], 2002, 90(3/4): 195-229.
  • 6HUANGYi(黄怡) ZHENGMin-Yan(郑敏燕) WANGShan(王珊) HUANGFang-Qian(黄方千) TIANWei(田威) FANXiao-Dong(范晓东) KANGQiong(康琼).高分子学报,2010,.
  • 7DeLong R., Stephenson K, Loftus T., Fisher M., Alahari S., Nolting A., Juliano R. L.. J. Pharm. Sci.[J]..1997, 86(6):762-764.
  • 8Yoo H., Juliano RL.. Nucleic Acids Res.[J]..2000, 28(21):4225-4231.
  • 9Kim T., Seo HJ., Choi J. S., Baek J., Kim K., Park J. S.. Biomacromolecules[J]..2004, 5(6):2487-2492.
  • 10Chen H. T., Neerman MF., Parrish A. R., Simanek E. E.. J. Am. Chem. Soc.[J]..2004, 126(32):10044-10048.

共引文献7

同被引文献34

  • 1Dolecek TA,Propp JM,Stroup NE, et al. CBTRUS statisti- cal report:primary brain and central nervous system tu- mors diagnosed in the United States in 2005-2009 [J]. Neuro Oncol,2012,14(5) :v1-v49.
  • 2Stupp R, Mason WP, van den Bent M J, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblas- toma [J], N Engl J Med, 2005,352(10) : 987-996.
  • 3Chen JJ,Juan SY. Editorial(thematic issue : emerging con- cepts and therapeutics strategies for the treatment of brain tumors) [J]. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14(8): 1063-1064.
  • 4An S, Jiang XT, Shi JS, et al. Single-component self-as- sembled RNAi nanoparticles functionalized with tumor- targeting iNGR delivering abundant siRNA for efficient glioma therapy [J], Biomaterials, 2015,53: 330-340.
  • 5Stupp R,Hegi ME,Mason WP.,et al. Effects of radiother- apy withconcomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a ran- domised phase Ⅲ study:5-year analysis of the EORTC- NCIC trial [J]. Lancet Oncol, 2009,10(5) :459-466.
  • 6Wang SJ, Zhao Y, Ruan ZC, et al. Association between EGF +61 G/A and glioma risk in a Chinese population [J]. BMC Cancer, 2010,10( 1 ) : 221.
  • 7Serguera C, Bemelmans AP. Gene therapy of the central nervous system:general considerations on viral vectors for gene transfer into the brain [J]. Revue Neurologique,2014, 170(12) : 727-738.
  • 8Wan ZF,Jung F,Wang WW,et al. Genetic engineering of mesenchymal stem cells by non-viral gene delivery [J].Clin Hemorheol Microcirc, 2014,58(1) : 19-48.
  • 9Meade BR,Dowdy SF. Enhancing the ceUular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides [J]. Adv Drug Deliv Rev, 2007,60 (4-5) : 530-536.
  • 10Li SD,Huang L. Stealth nanoparticles:high density but sheddable PEG is a key for tumor targeting [J]. J Control Release, 2010,145(3) : 178-181.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部